drugset / Trial / NCT03697226

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.

NCT03697226 ↗

Phase 1 Completed 8 enrolled Antiva Biosciences
Non-randomizedSequentialOpen-labelTreatment

Summary

This study evaluates the use of ABI-1968, a topical cream, in the treatment of cervical precancerous lesions in females without human immunodeficiency virus (HIV) infection.

Timeline

Start
2018-12-21
Primary completion
2020-05-26
Completion
2020-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ABI-1968 Unknown — Topical